Psychopharmacotherapy of mental disorders in hematological patients: security concerns

Close metadata

OBJECTIVE

Evaluation of the safety of psychopharmacotherapy (PFT) of mental disorders in modern protocols for the treatment of patients with blood disorders.

MATERIAL AND METHODS

The data of medical records of 552 patients with blood disorders who received PFT during treatment at the clinic of the National Medical Research Center for Hematology were analyzed. Any adverse events recorded while taking PFT were taken into account. Statistical analysis included descriptive statistics, frequency analysis, and assessment (Student’s t-test) of changes in blood parameters (before and after taking psychotropic drugs).

RESULTS

Signs of hematotoxicity were found only in 7.1% (n=37) patients, in all cases while taking benzodiazepines (n=12) in combination with hematotoxic drugs for the treatment of blood disorders. Other significant adverse events (which caused premature discontinuation or dose reduction) were detected in 4.8% (n=25) cases, of which 9 were associated with the appointment of anxiolytics (hydroxyzine, zopiclone), 11 with antidepressants (clomipramine, amitriptyline, duloxetine, trazodone, ademethionine) and 5 with antipsychotics (risperidone, alimemazine, haloperidol).

CONCLUSION

Most psychotropic drugs are effective in relation to psychopathological disorders that develop in hematological patients and are safe when used at minimum/average therapeutic doses within the daily dosage ranges established by the official instructions for use.

Keywords:

diseases of the blood system

psychotropic drugs

hematotoxicity

safety

Authors:

Vybornykh D.E.

National Medical Research Center for Hematology

ORCID: 0000-0001-7506-4947

Ivanov S.V.

Mental Health Research Center

ORCID: 0000-0001-9532-7150

Gemdzhian E.G.

National Medical Research Center for Hematology

ORCID: 0000-0002-8357-977X

Gaponova T.V.

National Medical Research Center for Hematology

ORCID: 0000-0002-9684-5045

Received:

21.11.2022

Accepted:

05.12.2022

List of references:

Malignant neoplasms In Russia in 2020 (morbidity and mortality). Edited by Kaprin A.D., Starinsky V.V., Shakhzadova A.O. M.: MNIOI im. P.A. Herzen; 2021;252. (In Russ.).
Vybornykh DE. Clinical and epidemiological study of a sample of patients with diseases of the blood system. Konsul’tativnaja Psihologija i Psihoterapija. 2014;1(80):64-89. (In Russ.).
Ivanov SV, Voronova EI. Depression therapy for somatic diseases. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5-2):106-112. (In Russ.). https://doi.org/10.17116/jnevro2021121052106
Vybornykh D.E. Effect of psychotropic drugs on the hematopoietic system. Social’naja i Klinicheskaja Psihiatrija. 2002;12(4):71-79. (In Russ.).
Balon R, Berchou R. Hematologic side effects of psychotropic drugs. Psychosomatics. 1986;27(2):119-120, 125-127. https://doi.org/10.1016/S0033-3182(86)72722-9
Brusov OS, Karpova NS, Factor MI, et al. Decreased procoagulant activity of blood plasma in patients with schizophrenia during pharmacotherapy: thrombodynamic parameters of coagulation before and after treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(10):51-55. (In Russ.). https://doi.org/10.17116/jnevro201911910151
Mazaira S. Efectos adversos hematológicos de los psicofármacos [Haematological adverse effects caused by psychiatric drugs]. Vertex. 2008;19(82):378-386.
Garcia-Rosa S, Carvalho BS, Guest PC, et al. Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. J Proteomics. 2020;224:103813. https://doi.org/10.1016/j.jprot.2020.103813
Vidal Handbook 2022. Medicines In Russia. Vidal Rus; 2022;1120. (In Russ.).
Sirota P, Stoler M, Meshulam B. Major depression with psychotic features associated with acyclovir therapy. Drug Intell Clin Pharm. 1988;4(22):306-308.
Dixon D, Craven J. Continuous infusion of haloperidol. Am J Psychiatry. 1993;150(4):673. https://doi.org/10.1176/ajp.150.4.673a
Michopoulos I, Christodoulou C, Dervenoulas J, et al. Quetiapine monotherapy in bipolar I disorder: a 1-year stabilization in a woman having undergone bone marrow transplantation. World J Biol Psychiatry. 2010;11:519-521. https://doi.org/10.3109/15622970701624587
Slaughter JR, Jain A, Holmes S, et al. Panic disorder in hospitalized cancer patients. Psychooncology. 2000;9(3):253-258. https://doi.org/10.1002/1099-1611(200005/06)9:3<253::aid-pon449>3.0.co;2-c
Ito M, Onose M, Yamada T, et al. Successful lithium carbonate treatment for steroid-induced depression following bone marrow transplantation: a case report. Jpn J Clin Oncol. 2003;33(10):538-540. https://doi.org/10.1093/jjco/hyg097
Ambanelli U, Manganelli P. Sifnificato clinico delle alterazioni del metabolismo del triptofano [Clinical significance of changes in tryptophan metabolism]. Ateneo Parmense Acta Biomed. 1975;46(1-2):5-19.
Goodman AB. Medical conditions in Ashkenazi schizophrenic pedigrees. Schizophr Bull. 1994;20(3):507-517. https://doi.org/10.1093/schbul/20.3.507
Schröder A, Weise K. Ein 20-jähriger Schizophrener mit akuter Leukämie [A 20-year-old schizophrenic patient with acute leukemia]. Psychiatr Prax. 1996;23(3):145.
Chamberlain FE, Walsh N, Falkowski J. Chemotherapy for Hodgkin’s lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005. B J Psych Bull. 2015;39(6):305-307. https://doi.org/10.1192/pb.bp.114.048306
Greenberg DR, Khandwala YS, Lu Y, et al. Disease burden in offspring is associated with changing paternal demographics in the United States. Andrology. 2020;8(2):342-347. https://doi.org/10.1111/andr.12700
Augustin NB, Maroules M. Hyperleukocytosis during clozapine treatment: A rare presentation of B-cell Acute lymphoblastic leukemia. Leuk Res Rep. 2021;15:100253. https://doi.org/10.1016/j.lrr.2021.100253
Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;70(1):1-10. https://doi.org/10.1023/a:1012518831494
Nazarenko GI, Kishkun AA. Clinical evaluation of laboratory results. M., 2005. (In Russ.).
Sanabria E, Cuenca RE, Esteso MÁ, Maldonado M. Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances. Toxics. 2021;9(2):25. https://doi.org/10.3390/toxics9020025
Gylvin SH, Jørgensen CC, Fink-Jensen A, et al. Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group. Psychopharmacologic treatment and blood transfusion in fast-track total hip and knee arthroplasty. Transfusion. 2017;57(4):971-976. https://doi.org/10.1111/trf.13992
Lopez-Vilchez I, Jerez-Dolz D, Diaz-Ricart M, et al. Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thromb Haemost. 2017;117(12):2312-2321.
Smith MM, Smith BB, Lahr BD, et al. Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgical Patients. Anesth Analg. 2018;126(6):1859-1866. https://doi.org/10.1213/ANE.0000000000002668
Belay ES, Penrose CT, Ryan SP, et al. Perioperative Selective Serotonin Reuptake Inhibitor Use Is Associated With an Increased Risk of Transfusion in Total Hip and Knee Arthroplasty. J Arthroplasty. 2019;34(12):2898-2902. https://doi.org/10.1016/j.arth.2019.04.057
Kraglund KL, Mortensen JK, Johnsen SP, et al. Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. Sci Rep. 2019;9(1):20048. https://doi.org/10.1038/s41598-019-56487-8
Mawardi G, Markman TM, Muslem R, et al. SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung Circ. 2020;29(8):1241-1246. https://doi.org/10.1016/j.hlc.2019.07.011

Close metadata